Germany - Drugs

Description

The participating health insurance funds pursue the goal of concluding rebate contracts with all suitable pharmaceutical companies in accordance with Section 130a (8) SGB V (for lots 1 and 2) or Section 130c (1) SGB V (for lot 3) for the active ingredients listed in the respective lot. The contract is concluded within the framework of the open-house biologics procedure of the participating health insurance funds: individual negotiations on the content of the contract are not conducted; uniform conditions apply. The participating health insurers do not guarantee exclusivity to individual contract partners. The contract period is a maximum of 24 months beginning on 01.08.2023. The contract ends on 31.07.2025 at the latest, irrespective of the date on which the contract was concluded. Irrespective of this, this procedure for Lot 1 and any contract concluded in the context of this procedure for Lot 1 shall automatically end upon the entry into force of the resolution of the Federal Joint Committee of June 15, 2023 on the amendment of the Medicinal Products Guideline: "Section 40b (new) - Exchange of biotechnologically produced biological finished medicinal products by pharmacies for parenteral preparations for direct medical use".For Lot 3, the following also applies: if the patent expires before July 31, 2025, the contract automatically ends at the end of the month in which the patent expires.All further information can be found in the participation and contract documents.
Joining this open house biologics procedure is possible at any time during the contract period.A contract will be concluded with all pharmaceutical companies that fulfill the requirements according to Annex 4 to the contract (self-declaration of approval and company) and confirm this in electronic form according to Section 126a of the German Civil Code (BGB).This announcement does not concern the award of a public contract within the meaning of the Public Procurement Directive (2014/24/EC) or antitrust law. In the interest of providing the broadest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The designation of the procedure "Open Procedure" according to IV.1.1) and the specification of the award criteria according to II.2.5) used in the text of this announcement are due to the requirements of the announcement form and have no further meaning. Neither this nor the use of the "TED" medium is in any way connected with submission to procurement law regulations, the application of which is not mandatory by law or procurement regulations. Due to the existence of industrial property rights with regard to the active ingredient covered by the agreement, the participation and contract documents will only be made available to those pharmaceutical companies that offer/market drugs containing the active ingredient covered by the agreement or that can credibly demonstrate to TK that they offer/market drugs containing the active ingredient covered by the agreement. A contract will be concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration of marketing authorization and company) and confirm this in electronic form in accordance with Section 126a of the German Civil Code (BGB).This announcement does not relate to the award of a public contract within the meaning of the Public Procurement Directive (2014/24/EC) or antitrust law. In the interest of providing the broadest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The designation of the procedure "Open Procedure" according to IV.1.1) and the specification of the award criteria according to II.2.5) used in the text of this announcement are due to the requirements of the announcement form and have no further meaning. Neither this nor the use of the "TED" medium is in any way connected with submission to procurement law regulations, the application of which is not mandatory by law or procurement regulations.

Opportunity closing date

31 July 2025

Value of contract

to be confirmed